Spark Newswire Spark Newswire
  • Newswire
  • News
    • Guidance
    • Dividends
    • M&A
    • Buybacks
    • Legal
    • Interviews
    • Management
    • Offerings
    • IPOs
    • Insider Trades
    • Biotech/FDA
    • Tech
  • Markets
    • After Hours
    • Movers
    • ETFs
    • Forex
    • Commodities
    • Options
    • Binary Options
    • Bonds
    • Futures
    • Global Economics
    • Reviews
    • Small-Cap
    • Cryptocurrency
    • Penny Stocks
  • Analysts
    • Analyst Color
    • Analyst Ratings
    • Upgrades
    • Downgrades
  • Earnings
    • Earnings
  • Support & Feedback
  • Registration Options
  • Log In
News by Category
  • After-Hours Center
  • Analyst Color
  • Analyst Ratings
  • Asia
  • Asset Sales
  • Binary Options
  • Biotech
  • Bonds
  • Broad U.S. Equity ETFs
  • Buybacks
  • Cannabis
  • Commodities
  • Contracts
  • Crowdsourcing
  • Cryptocurrency
  • Currency ETFs
  • Dividends
  • Downgrades
  • Earnings
  • Earnings Beats
  • Earnings Misses
  • Econ #s
  • Economics
  • Education
  • Emerging Market ETFs
  • Emerging Markets
  • Entertainment
  • Entrepreneurship
  • ESG
  • ETFs
  • Eurozone
  • Events
  • Exclusives
  • FDA
  • Federal Reserve
  • Financial Advisors
  • Financing
  • Fintech
  • Forex
  • Futures
  • Gaming
  • General
  • Global
  • Government
  • Guidance
  • Health Care
  • Hedge Funds
  • Hot
  • Initiation
  • Insider Trades
  • Insurance
  • Interview
  • Intraday Update
  • IPOs
  • Large Cap
  • Latin America
  • Legal
  • Long Ideas
  • M&A
  • Macro Economic Events
  • Management
  • Market-Moving Exclusives
  • Markets
  • Media
  • Mid Cap
  • Movers
  • Movers & Shakers
  • Mutual Funds
  • New ETFs
  • News
  • Offerings
  • Opinion
  • Options
  • Penny Stocks
  • Personal Finance
  • Politics
  • Pre-Market Outlook
  • Press Releases
  • Previews
  • Price Target
  • Psychedelics
  • Psychology
  • Real Estate
  • Regulations
  • REIT
  • Reiteration
  • Restaurants
  • Retail Sales
  • Reviews
  • Rumors
  • SEC
  • Sector ETFs
  • Short Ideas
  • Short Sellers
  • Signals
  • Small Business
  • Small Cap
  • Small Cap Analysis
  • Small-Cap
  • Social Media
  • SPACE
  • Specialty ETFs
  • Sports
  • Sports Betting
  • Startups
  • Stock Split
  • Success Stories
  • Tech
  • Technicals
  • Termination
  • Top Stories
  • Topics
  • Trading Ideas
  • Travel
  • Treasuries
  • Uncategorized
  • Upgrades
Spark Newswire Spark Newswire
Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.
  • Newswire
  • News
    • Guidance
    • Dividends
    • M&A
    • Buybacks
    • Legal
    • Interviews
    • Management
    • Offerings
    • IPOs
    • Insider Trades
    • Biotech/FDA
    • Tech
  • Markets
    • After Hours
    • Movers
    • ETFs
    • Forex
    • Commodities
    • Options
    • Binary Options
    • Bonds
    • Futures
    • Global Economics
    • Reviews
    • Small-Cap
    • Cryptocurrency
    • Penny Stocks
  • Analysts
    • Analyst Color
    • Analyst Ratings
    • Upgrades
    • Downgrades
  • Earnings
    • Earnings
  • Support & Feedback
  • Registration Options
  • Log In
Spark Newswire Spark Newswire
Filter By Ticker
Search By Date To
Today | Yesterday | This week

Latest news

Group By Ticker
Sort By
Newest | Oldest
Read More
1 minute read
  • News

Horizon Therapeutics Announced New Analysis Of MRI Findings Show UPLIZNA Reduced The Formation of Asymptomatic Optic Nerve Lesions In People With Neuromyelitis Optica Spectrum Disorder

By Charles Gross
Today, 11:33 AM
Horizon Therapeutics plc (Nasdaq: HZNP) today announced the presentation of new MRI imaging data from the Phase 3 clinical trial showing UPLIZNA reduced the formation of subclinical (asymptomatic) optic nerve lesions in people with NMOSD.

HZNP

Read More
2 minute read
  • Intraday Update
  • Markets
  • News

Horizon Therapeutics’ Debt Overview

By Benzinga Insights
Today, 11:33 AM
Over the past three months, shares of Horizon Therapeutics Inc. (NASDAQ:HZNP) increased by 13.37%. When understanding a companies…

HZNP

Read More
1 minute read
  • Dividends
  • Earnings
  • News

Here’s How Much You Would Have Made Owning Horizon Therapeutics Stock In The Last 5 Years

By Benzinga Insights
Today, 11:33 AM
Horizon Therapeutics (NASDAQ:HZNP) has outperformed the market over the past 5 years by 40.09% on an annualized basis…

HZNP

Read More
1 minute read
  • Earnings
  • News

Horizon Therapeutics Q4 Adjusted EPS $1.21 Beats $1.09 Estimate, Sales $942.00M Beat $922.92M Estimate

By Benzinga Newsdesk
Today, 11:33 AM
Horizon Therapeutics (NASDAQ:HZNP) reported quarterly earnings of $1.21 per share which beat the analyst consensus estimate of $1.09 by 11.01 percent. This is a 14.18 percent decrease over earnings of $1.41 per share

HZNP

Read More
11 minute read
  • Earnings

Earnings Scheduled For March 1, 2023

By Benzinga Insights
Today, 11:33 AM
Companies Reporting Before The Bell • Globalstar (AMEX:GSAT) is expected to report quarterly loss at $0.01 per share on revenue of $38.75 million.

AAN

Read More
1 minute read
  • Biotech
  • Earnings
  • General
  • Health Care
  • Large Cap
  • News

Amgen Records Slight Fall In Quarterly Earnings; Lower COVID-19 Manufacturing Pacts Impact Bottomline

By Vandana Singh
Today, 11:33 AM
Amgen Inc’s (NASDAQ:AMGN) fourth-quarter revenues were $6.84 billion, beating the consensus of $6.76 billion, largely unchanged from Q4 2021, and…

ABBV

Read More
1 minute read
  • Analyst Color
  • Analyst Ratings
  • Biotech
  • General
  • Health Care
  • News
  • Penny Stocks
  • Price Target
  • Reiteration

Analyst Says Selecta Biosciences’ Gout Candidate Can Potentially Raise The Bar On Several Fronts

By Vandana Singh
Today, 11:33 AM
Canaccord Genuity has increased the price target for Selecta Biosciences Inc (NASDAQ:SELB) from $9 to $10 while maintaining the Buy rating ahead of…

ALPMF

Read More
1 minute read
  • Legal
  • M&A
  • News

U.S. Senator Elizabeth Warren Writes FTC To Express Concern About Two Pharmaceutical Deals; Warren Tells Agency She Is “Particularly Concerned” About Amgen Plan To Buy Horizon Therapeutics And Indivior’s Plan To Buy Opiant Pharmaceuticals

By Benzinga Newsdesk
Today, 11:33 AM
- Reuters

AMGN

Read More
1 minute read
  • Biotech
  • General
  • Health Care
  • News

Horizon Therapeutics Touts Positive Data From Mid-Stage Study For Immune System Disorder

By Vandana Singh
Today, 11:33 AM
Horizon Therapeutics plc’s (NASDAQ:HZNP) Phase 2 trial evaluating dazodalibep for Sjögren’s syndrome met its primary endpoint in the second patient…

HZNP

Read More
4 minute read
  • Options

10 Health Care Stocks Whale Activity In Today’s Session

By Benzinga Insights
Today, 11:33 AM
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner.

ALGN

Posts navigation

1 2 … 14 Next
Free Newsletter subscribe

Stock Market Ideas & Analysis

Stay up-to-date with the same information professionals use.
Spark Newswire Spark Newswire
  • Newswire
  • Registration
  • Log In
  • Settings
  • Privacy Policy
  • Terms of Service
© 2021 Spark Newswire
All Rights Reserved.

All news is property of their respective owners. Terms of Service